Ken Griffin
DSGN icon

Ken Griffin’s Design Therapeutics DSGN Stock Holding History

Ken Griffin’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.46M Sell
231,513
-228,361
-50% -$2.31M ﹤0.01% 5655
2025
Q4 		$4.31M Sell
459,874
-94,146
-17% -$737K ﹤0.01% 4509
2025
Q3 		$4.17M Sell
554,020
-286,773
-34% -$1.44M ﹤0.01% 4686
2025
Q2 		$2.83M Sell
840,793
-122,667
-13% -$459K ﹤0.01% 5067
2025
Q1 		$3.72M Buy
963,460
+4,667
+0.5% +$22.3K ﹤0.01% 4381
2024
Q4 		$5.92M Buy
958,793
+383,243
+67% +$2.22M ﹤0.01% 3699
2024
Q3 		$3.1M Buy
575,550
+270,920
+89% +$1.27M ﹤0.01% 4723
2024
Q2 		$1.02M Sell
304,630
-570,147
-65% -$2.22M ﹤0.01% 6536
2024
Q1 		$3.53M Sell
874,777
-957,477
-52% -$2.56M ﹤0.01% 4534
2023
Q4 		$4.86M Sell
1,832,254
-868,299
-32% -$1.99M ﹤0.01% 3838
2023
Q3 		$6.37M Sell
2,700,553
-155,553
-5% -$726K ﹤0.01% 3286
2023
Q2 		$18M Sell
2,856,106
-9,061
-0.3% -$55.4K ﹤0.01% 1993
2023
Q1 		$16.5M Buy
2,865,167
+362,606
+14% +$2.71M ﹤0.01% 2146
2022
Q4 		$25.7M Buy
2,502,561
+80,829
+3% +$1.1M 0.01% 1703
2022
Q3 		$40.5M Sell
2,421,732
-123,926
-5% -$2.47M 0.01% 1236
2022
Q2 		$35.6M Buy
2,545,658
+10,956
+0.4% +$148K 0.01% 1305
2022
Q1 		$40.9M Hold
2,534,702
– – 0.01% 1267
2021
Q4 		$54.3M Sell
2,534,702
-37,828
-1% -$650K 0.01% 1104
2021
Q3 		$37.8M Buy
2,572,530
+6,382
+0.2% +$106K 0.01% 1339
2021
Q2 		$49.9M Buy
2,566,148
+31,445
+1% +$794K 0.01% 1126
2021
Q1 		$75.8M Buy
+2,534,703
New +$85.5M 0.02% 744

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ken Griffin's DSGN Position: Q1 2026 in Review

Ken Griffin reduced its Design Therapeutics (DSGN) stake by 50% in Q1 2026, selling an estimated $2.31M and leaving 231,513 shares worth $2.46M. The position accounts for ﹤0.01% of the portfolio, ranked #5655.

Ken Griffin first reported a position in DSGN in Q1 2021 and has held it in 21 quarters since. The position peaked at $75.8M in Q1 2021. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Ken Griffin held 231,513 shares of Design Therapeutics worth $2.46M as of Q1 2026.
  • Ken Griffin sold 228,361 Design Therapeutics shares in Q1 2026, an estimated $2.31M.
  • Design Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #5655 holding.
  • Ken Griffin first reported a position in Design Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Ken Griffin's Design Therapeutics position peaked at $75.8M in Q1 2021.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.